Kevin Elder has been appointed CFO for Bio-Matrix Scientific Group (San Diego), a development-stage company focused on medical devices and monitoring systems. Elder most recently served as CFO of StereoVision.

Gene Saragnese has been promoted to vice president and general manager of GE Healthcare's (Waukesha, Wis-consin) global Functional and Computed Tomography (FCT) business. Saragnese replaces Peter Arduini, who will leave the company in early April. Saragnese, a career veteran of GE and a GE officer, formerly led GE Healthcare's Global Technology organization. GE's FCT business develops CT systems, as well as positron emission tomography/computed tomography, nuclear medicine and radiopharmacy systems.

Rodney Hildebrandt has been named chief operating officer and a director of Recom Managed Systems (Los Angeles). He has more than 30 years' experience at Johnson & Johnson, where he filled numerous high-level executive roles. Marvin Fink and Robert Koblin have retired as directors of Recom, although Fink remains CEO in a somewhat reduced role to assure operational and transitional integrity as the company now moves to commercialization of its products. Recom is focused on the monitoring and detection of disease through continuous biomedical signal monitoring.

Linda Rubinstein has been named vice president of Solexa (Hayward, California). Rubinstein will assume the position of CFO following the filing of Solexa's annual report on Form 10-K for the year ended Dec. 31, 2004. Kathy San Roman, who currently holds the position of acting CFO, will continue as vice president of human resources and administration. Rubinstein brings to Solexa more than 16 years of life sciences industry and financial experience, including serving as principal of RDJ Advisors and as vice president of finance of ChemoCentryx. Solexa is developing and preparing to commercialize a new platform for genetic analysis, based on Sequencing-by-Synthesis and molecular arrays.

David Ladner, PhD, has been named to lead the newly formed department of licensing and patents at Xenomics (New York). Ladner for the past five years has been a manager of intellectual property in the pharmaceutical division of Bayer Pharma. Xenomics is developing gateway DNA testing technology designed to expand the field of molecular diagnostics.